Voxzogo (vosoritide)
BioMarin Pharmaceutical (BMRN)
Decision dateFeb 28, 2027
105 days away
Marketer take
Full approval lands weeks after the oral infigratinib decision, so the incumbent brand will likely lean on its long-term data.
- Sponsor company
- BioMarin Pharmaceutical (BMRN)
- Indication
- Achondroplasia in children, full approval (sNDA)
- Therapeutic area
- Endocrinology, Rare disease
- Event
- PDUFA target action date
- Date
- Feb 28, 2027
- Status
- Upcoming
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?